American Association of Individual Investors5d
Is Eisai Stock (ESALY) a Good Investment?
The value score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, ...
Context6d
Geisha District Night Tour: Exploring Gion
Step into the serenity of Kennin-ji, the city's oldest Zen temple, and the location of the burial site of Eisai, the monk who introduced Zen ... please let our team know at the time of booking. Book ...
Nasdaq4d
Eisai Gets Positive Opinion From CHMP In European Union For Lecanemab In Early Alzheimer's Disease
(RTTNews) - Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced a positive opinion has been received from the Committee for Medicinal Products for Human Use (CHMP) of the European ...
The Hindu4d
EU regulator backs Eisai-Biogen Alzheimer’s drug
The European Union’s drugs regulator on Thursday (November 14, 2024) recommended approval of Eisai and Biogen’s Leqembi for some patients with early Alzheimer’s disease, reversing its ...
Morningstar5d
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease
TOKYO and CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB ...
Reuters4d
EU regulator backs Eisai-Biogen Alzheimer's drug after initial rejection
Nov 14 (Reuters) - The European Union's drugs regulator on Thursday recommended approval of Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab Leqembi for some patients with early ...
FiercePharma5d
EMA changes tune, endorses Eisai and Biogen's Leqembi in restricted Alzheimer's population
Upon reexamination, the European Medicines Agency has made a U-turn on Eisai and Biogen’s Alzheimer’s disease drug Leqembi. After a rejection in July, drug reviewers at the EMA have now ...
Morningstar5d
Biogen, Eisai Win CHMP Backing of Leqembi Alzheimer's Drug
A key European regulatory panel has reversed course and is now recommending approval of Leqembi, the Alzheimer's drug from Biogen and Eisai. The companies on Thursday said the European Medicines ...
FiercePharma4d
EU regulators endorse meds from BMS, J&J, Eisai and more—plus a clutch of biosims
In making its reexamination, the CHMP weighed subgroup analyses from Eisai showing that 8.9% and 12.9% of patients in the drug’s restricted population experienced ARIA brain swelling or bleeding ...
STAT5d
Changing course, European regulators now say Alzheimer’s treatment Leqembi should be approved
LONDON — Reversing an earlier decision, European regulators on Thursday recommended that an Alzheimer’s therapy from Eisai and Biogen should be approved, saying that the benefits of the ...
The New York Times1d
Book Review
By Elisabeth Egan Recent books by Minsoo Kang, Margaret Killjoy and James S.A. Corey. By Amal El-Mohtar “The City and Its Uncertain Walls” features all the author’s signature elements ...
pharmaphorum1d
Eisai, Biogen eye 2025 approval for Leqembi autoinjector
Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on ...